Clinical Trial Update: A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the safety and tolerability of AZD5213 on sleep in patients with mild cognitive impairment or mild Alzheimer's disease; the study is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Cognitive Impairment

Drugs mentioned

• AZD5213 (AZD5213)

Snippet

Sponsor: AstraZeneca | Conditions: Mild Cognitive Impairment, Mild Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2016-12-05